title: Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
abstract: Men receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prostate cancer (mCRPC). Whilst effective treatment options for mCRPC have traditionally been limited, new agents are becoming available. Since 2010, the number and class of agents available to treat mCRPC has increased dramatically. As such, there is a need for clear guidance on the optimum treatment and sequence of treatments for mCRPC before and after chemotherapy. This evidence-based statement, reflecting the views of the authors, provides suggestions on the continued relevance of conventional approaches to first- and second-line treatment in mCRPC, the potential role of novel treatments, and factors that may influence the choice of hormonal agents and/or chemotherapy.
authors.affiliation: University Hospital, Saint Etienne, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mottet
authors.forename: Noel
authors.initials: N
authors.lastname: Clarke
authors.forename: Maria
authors.initials: M
authors.lastname: De Santis
authors.forename: Filiberto
authors.initials: F
authors.lastname: Zattoni
authors.forename: Juan
authors.initials: J
authors.lastname: Morote
authors.forename: Steven
authors.initials: S
authors.lastname: Joniau
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D057285:Precision Medicine; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents
keywords: castrate-resistant prostate cancer; evidence-based best practice; individualised management; new agents